Article

Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders

Department of Neurology, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK.
Neuromuscular Disorders (Impact Factor: 3.13). 02/2005; 15(1):17-23. DOI: 10.1016/j.nmd.2004.10.002
Source: PubMed

ABSTRACT While skeletal muscles generally perform specific limited roles, extraocular muscles (EOMs) have to be responsive over a wider dynamic range. As a result, EOMs have fundamentally distinct structural, functional, biochemical and immunological properties compared to other skeletal muscles. While these properties enable high fatigue resistance and the rapid and precise control of extraocular motility, they might also explain why EOMs are selectively involved in certain disorders, such as chronic progressive external ophthalmoplegia (CPEO), myasthenia gravis and Graves' ophthalmopathy. This review first gives an overview of the novel myofibre classification in EOMs and then focuses on those properties that might explain why ophthalmoplegia should be so prominent in these disorders.

Download full-text

Full-text

Available from: Cynthia Yu-Wai-Man, Aug 23, 2014
0 Followers
 · 
59 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: As with many skeletal muscle diseases, the extraocular muscles (EOMs) are spared in skeletal muscle alpha-actin diseases, with no ophthalmoplegia even in severely affected patients. We hypothesised that the extraocular muscles sparing in these patients was due to significant expression of cardiac alpha-actin, the alpha-actin isoform expressed in heart and foetal skeletal muscle. We have shown by immunochemistry, Western blotting and a novel MRM-mass spectrometry technique, comparable levels of cardiac alpha-actin in the extraocular muscles of human, pig and sheep to those in the heart. The sparing of extraocular muscles in skeletal muscle alpha-actin disease is thus probably due to greater levels of cardiac alpha-actin, than the negligible amounts in skeletal muscles, diluting out the effects of the mutant skeletal muscle alpha-actin.
    Neuromuscular Disorders 11/2008; 18(12):953-8. DOI:10.1016/j.nmd.2008.09.010 · 3.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ocular myositis represents a subgroup within the idiopathic orbital inflammatory syndrome, formerly termed orbital pseudotumor. Ocular myositis describes a rare inflammatory disorder of single or multiple extraocular eye muscles. Unilateral or sequential bilateral subacute painful diplopia is the leading symptom of eye muscle myositis. There are at least two major forms, a limited oligosymptomatic ocular myositis (LOOM) with additional conjunctival injections only, and a severe exophthalmic ocular myositis (SEOM) with additional ptosis, chemosis, and proptosis. Eye muscle myositis is an idiopathic inflammation of the extraocular muscles in the absence of thyroid disease, ocular myasthenia gravis, and other systemic, particularly autoimmune mediated diseases, resembling CD4(+) T cell-mediated dermatomyositis. Contrast-enhanced orbital magnetic resonance imaging most sensitively discloses swelling, signal hyperintensity, and enhancement of isolated eye muscles. Typically, corticosteroid treatment results in prompt improvement and remission within days to weeks in most patients. Compiled data of five patients and a review of the clinical pattern, diagnostic procedures, differential diagnoses, and current treatment options are given.
    Clinical ophthalmology (Auckland, N.Z.) 04/2007; 1(1):37-42.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myasthenia gravis is an antibody-mediated disorder of neuromuscular transmission that is characterized by weakness and fatigue of voluntary muscles. Weakness may be ocular, bulbar, or generalized. Diagnostic evaluation of patients consists of bedside assessment, antibody testing, and electrophysiologic studies. Various therapeutic options are available, which consist of anticholinesterase inhibitors for symptomatic management, immunosuppressive agents as maintenance therapy, and thymectomy. Plasmapheresis and intravenous immunoglobulin are used in patients in crisis or those with rapidly worsening or refractory symptoms. In our article, we elaborate on key aspects of the epidemiology, pathogenesis, diagnostic evaluation, and therapeutic options for patients with myasthenia gravis.
    10/2013; 41(4):40-50. DOI:10.3810/hp.2013.10.1079